Balazs Halmos, MD, discussed the potential impact of subcutaneous amivantamab for patients with EGFR-mutated NSCLC. Halmos oversees the thoracic clinical trials program of novel clinical studies at ...
Counseling patients with obstructive sleep apnea on using GLP-1s effectively prior to starting treatment can help ensure adherence, said Matthew Biszewski, PharmD. Effective patient counseling is ...
Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...
Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation strategies, said Sara Assaf, MD. There are significant long-term systemic risks ...
Comprehensive screening for autoimmune retinopathy is essential in MG patients to prevent vision impairment due to symptom overlap. The study identified antiretinal antibodies and retinal ...
The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged 12 years and older with inadequately controlled chronic rhinosinusitis ...
Overall survival (OS) data, published simultaneously by the Journal of Clinical Oncology, 2 show the longest survival data ever seen in these patients, who typically were treated with chemotherapy ...
TeleMAB requests doubled post-Dobbs, with higher demand among those far from clinics and seeking early pregnancy care. A study in 18 states showed increased teleMAB demand correlating with distance ...
Panelists discuss how diuretics serve as necessary “bailout therapy” for volume management in heart failure but should not substitute for guideline-directed medical therapy, with emerging evidence ...
Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC. This transcript has been edited for length ...
Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...
For oncologists, seeing more young patients also raises the question of what happens after treatment, and this prompted the European Society for Medical Oncology (ESMO) to schedule a session, “Beyond ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback